<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370070</url>
  </required_header>
  <id_info>
    <org_study_id>NPC024</org_study_id>
    <nct_id>NCT01370070</nct_id>
  </id_info>
  <brief_title>MK-2206 in Recurrent Nasopharyngeal Carcinoma</brief_title>
  <acronym>MC1079</acronym>
  <official_title>Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <brief_summary>
    <textblock>
      To evaluate the activity and safety of MK-2206 in patients with recurrent or metastatic&#xD;
      nasopharyngeal carcinoma (NPC)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients alive and progression-free at 6 months along with the confirmed response rate as a dual primary endpoint</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RECIST-based subjective response</measure>
    <time_frame>3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory correlates: pharmacokinetics, plasma EBV DNA half-life</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment tolerability</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Recurrent Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>MK-2206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-2206</intervention_name>
    <description>200mg weekly repeated q 28 days</description>
    <arm_group_label>MK-2206</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged &gt; 18 year, able to give written informed consent.&#xD;
&#xD;
          -  History of histologically or cytologically confirmed non-keratinizing NPC that has&#xD;
             recurred at locoregional and/or distant sites, and is not amenable to potentially&#xD;
             curative radiotherapy or surgery.&#xD;
&#xD;
          -  Patients must have progressed within 24 months of receiving one or two prior line of&#xD;
             chemotherapy for recurrent disease, of which at least one line must contain platinum&#xD;
             drugs such as Cisplatin, Carboplatin or oxaliplatin.&#xD;
&#xD;
          -  Adequate organ reserve: neutrophils &gt;1.5x109/L, platelets ≥100 x109/L, hemoglobin ≥9&#xD;
             g/dL, serum alanine aminotransferase (ALT) &lt; 2.5 x upper limit of normal (ULN) or ALT&lt;&#xD;
             5 x ULN in the presence of liver metastases, serum bilirubin &lt; 2.5 x ULN, serum&#xD;
             creatinine &lt; 1.5 x ULN.&#xD;
&#xD;
          -  Presence of measurable disease as per Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST ver 1.1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy, radiotherapy (except to bone metastases) or investigational treatment&#xD;
             within 4 weeks of enrollment.&#xD;
&#xD;
          -  Patients with diabetes or in risk for hyperglycemia should not be excluded from trials&#xD;
             with MK-2206, but the hyperglycemia should be well controlled before the patient&#xD;
             enters the trial.&#xD;
&#xD;
          -  Cardiovascular: baseline QTcF &gt; 450 msec (male) or QTcF &gt;470 msec (female) Left bundle&#xD;
             branch block, 2nd or 3rd degree AV block, bifascicular block, sick sinus syndrome,&#xD;
             Wolff-Parkinson-white syndrome, significant sinus bradycardia (&lt; 50bpm) . However,&#xD;
             patients with asymptomatic right bundle branch block or 1st degree AV block, in the&#xD;
             absence of known cardiac disease (e.g. coronary, valvular) are NOT excluded..&#xD;
&#xD;
          -  Uncontrolled inter-current illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigette Ma, MD, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CCTU</investigator_full_name>
    <investigator_title>Comprehensive Cancer Trial Units</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

